Malgorzata Poreba and Pawel Rostoff contributed equally to this work
There are inconsistent data about the role of serum phospholipid fatty acid composition in patients with type 2 diabetes (T2DM) and atherosclerotic cardiovascular disease (ASCVD). The aim of the study was to investigate the relationship between serum phospholipid fatty acid composition, systemic low-grade inflammation, and glycemic control in high-risk T2DM patients.
Seventy-four patients (26% women, mean age 65.6 ± 6.8 years) with T2DM (median diabetes duration 10 years) and documented ASCVD (74 with coronary artery disease, 26 with peripheral arterial disease) were enrolled in the study. Baseline HbA1c was estimated using turbidimetric inhibition immunoassay. According to the median value of HbA1c the patients were grouped into those with HbA1c < 7.0% (< 53 mmol/mol) (n = 38) and those with HbA1c ≥ 7.0% (≥ 53 mmol/mol) (n = 36). Serum phospholipid fatty acids were measured with gas chromatography.
Patients with HbA1c ≥ 7.0%, compared with those with HbA1c < 7.0% had similar composition of saturated and monounsaturated fatty acids in serum phospholipids, but had higher concentrations of linoleic acid (LA) and higher n-6/n-3 polyunsaturated fatty acid (PUFA) ratio as well as lower levels of eicosapentaenoic acid (EPA), total n-3 PUFAs, and the EPA/arachidonic acid ratio. We found that LA (r = 0.25; p = 0.03) and n-6/n-3 PUFA ratio (r = 0.28; p = 0.02) were positively correlated with HbA1c. Multivariate logistic regression analysis showed that n-6/n-3 PUFA ratio, hsCRP and T2DM duration were independent predictors of worse glycemic control in patients with T2DM and ASCVD.
This study showed that glycemic control in high-risk T2DM patients with ASCVD was significantly associated with unfavorable serum phospholipid n-6/n-3 PUFA ratio and greater systemic inflammation.
American Diabetes Association. 9. Cardiovascular disease and risk management. Diabetes Care. 2017;40(Suppl 1):S75–87. CrossRef
Gajos G, Piłaciński S, Zozulińska-Ziółkiewicz D. Controversies in diabetes in 2013—a brief update. Adv Clin Exp Med. 2013;22:777–84. PubMed
Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus—mechanisms, management, and clinical considerations. Circulation. 2016;133:2459–502. CrossRefPubMedPubMedCentral
Gajos G, Mostowik M. Low blood glucose in type 2 diabetes: a lot more to come? Pol Arch Med Wewn. 2016;126:1019–20. PubMed
Piątkiewicz P, Buraczewska-Leszczyńska B, Kuczerowski R, Bernat-Karpińska M, Rabijewski M, Kowrach M. Severe hypoglycaemia in elderly patients with type 2 diabetes and coexistence of cardiovascular history. Kardiol Pol. 2016;74:779–85. PubMed
Gumprecht J, Nabrdalik K. Hypoglycemia in patients with insulin-treated diabetes. Pol Arch Med Wewn. 2016;126:870–8. PubMed
Takahashi M, Ando J, Shimada K, Nishizaki Y, Tani S, Ogawa T, et al. The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated with diabetes mellitus in patients with prior myocardial infarction: a multicenter cross-sectional study. BMC Cardiovasc Disord. 2017;17:41. CrossRefPubMedPubMedCentral
Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol. 2010;55:1671–8. CrossRefPubMed
Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Epidemiology and Prevention, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135:e867–84. CrossRefPubMed
ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Jung H, et al. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309–18. CrossRef
Poreba M, Mostowik M, Siniarski A, Golebiowska-Wiatrak R, Malinowski KP, Haberka M, et al. Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes. Cardiovasc Diabetol. 2017;16:50. CrossRefPubMedPubMedCentral
Kurotani K, Sato M, Ejima Y, Nanri A, Yi S, Pham NM, et al. High levels of stearic acid, palmitoleic acid, and dihomo-γ-linolenic acid and low levels of linoleic acid in serum cholesterol ester are associated with high insulin resistance. Nutr Res. 2012;32(669–675):e3.
Flachs P, Rossmeisl M, Kopecky J. The effect of n-3 fatty acids on glucose homeostasis and insulin sensitivity. Physiol Res. 2014;63(Suppl 1):S93–118. PubMed
Li D. Omega-3 polyunsaturated fatty acids and non-communicable diseases: meta-analysis based systematic review. Asia Pac J Clin Nutr. 2015;24:10–5. PubMed
Coelho OG, da Silva BP, Rocha DM, Lopes LL, Alfenas RCG. Polyunsaturated fatty acids and type 2 diabetes: impact on the glycemic control mechanism. Crit Rev Food Sci Nutr. 2017;57:3614–9. CrossRef
Kusunoki M, Tsutsumi K, Nakayama M, Kurokawa T, Nakamura T, Ogawa H, et al. Relationship between serum concentrations of saturated fatty acids and unsaturated fatty acids and the homeostasis model insulin resistance index in Japanese patients with type 2 diabetes mellitus. J Med Investig. 2007;54:243–7. CrossRef
Sawada T, Tsubata H, Hashimoto N, Takabe M, Miyata T, Aoki K, et al. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial. Cardiovasc Diabetol. 2016;15:121. CrossRefPubMedPubMedCentral
Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med. 2008;233:674–88. CrossRef
Rosqvist F, Bjermo H, Kullberg J, Johansson L, Michaëlsson K, Ahlström H, et al. Fatty acid composition in serum cholesterol esters and phospholipids is linked to visceral and subcutaneous adipose tissue content in elderly individuals: a cross-sectional study. Lipids Health Dis. 2017;16:68. CrossRefPubMedPubMedCentral
Mazidi M, Kengne AP, Banach M. Mineral and vitamin consumption and telomere length among adults in the United States. Pol Arch Intern Med. 2017;127:87–90. PubMed
Sanak M, Plutecka H, Szczeklik W, Piwowarska W, Rostoff P, Szczeklik A. Functional promoter polymorphism of cyclooxygenase-2 modulates the inflammatory response in stable coronary heart disease. Pol Arch Med Wewn. 2010;120:82–8. PubMed
- Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II